These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


346 related items for PubMed ID: 30744539

  • 1. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G, Wang J, Ding P, Wen Y, Yang L.
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, Dingemans AMC, Lolkema MP, Paats MS, Dubbink HJ.
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [Abstract] [Full Text] [Related]

  • 4. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ.
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [Abstract] [Full Text] [Related]

  • 5. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
    Shalata W, Yakobson A, Weissmann S, Oscar E, Iraqi M, Kian W, Peled N, Agbarya A.
    Oncology; 2022 Aug; 100(9):467-474. PubMed ID: 35679833
    [Abstract] [Full Text] [Related]

  • 6. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.
    Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.
    Clin Cancer Res; 2018 Dec 01; 24(23):5963-5976. PubMed ID: 30072474
    [Abstract] [Full Text] [Related]

  • 7. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W, Shan B, Liu H, Zhou S, Li W, Pan J, Lin L, Hu D, Pan Y.
    J Thorac Oncol; 2019 Jul 01; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract] [Full Text] [Related]

  • 8. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
    Pruis MA, Paats MS, Geurts WRR, Dubbink HJ, Dingemans AC.
    JCO Precis Oncol; 2021 Nov 01; 5():849-853. PubMed ID: 34994615
    [No Abstract] [Full Text] [Related]

  • 9. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W, Wang H, Lu P, Yu Z, Xu C, Zhuang W, Song Z.
    J Transl Med; 2019 Feb 21; 17(1):52. PubMed ID: 30791921
    [Abstract] [Full Text] [Related]

  • 10. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping.
    Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    In Vivo; 2020 Feb 21; 34(3):1399-1406. PubMed ID: 32354937
    [Abstract] [Full Text] [Related]

  • 11. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY, Liu LS, Zhang HY, Lu CH, Guo XY, Zhang LY, Yuan XB, Xue HH.
    Medicine (Baltimore); 2021 Jan 29; 100(4):e24300. PubMed ID: 33530219
    [Abstract] [Full Text] [Related]

  • 12. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Wang Y, Chen Z, Han X, Li J, Guo H, Shi J.
    Oncologist; 2021 Mar 29; 26(3):178-181. PubMed ID: 33000474
    [Abstract] [Full Text] [Related]

  • 13. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
    Kauffmann-Guerrero D, Kahnert K, Kumbrink J, Syunyaeva Z, Tufman A, Huber RM.
    Clin Lung Cancer; 2019 Jan 29; 20(1):59-62. PubMed ID: 30341016
    [No Abstract] [Full Text] [Related]

  • 14. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Rosenberg EH, Heideman DAM, Radonic T, Smit EF.
    Lung Cancer; 2018 Oct 29; 124():130-134. PubMed ID: 30268451
    [Abstract] [Full Text] [Related]

  • 15. Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Schrock AB, Lai A, Ali SM, Miller VA, Raez LE.
    J Thorac Oncol; 2017 Jul 29; 12(7):e89-e90. PubMed ID: 28629543
    [No Abstract] [Full Text] [Related]

  • 16. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.
    Cancer Sci; 2018 May 29; 109(5):1493-1502. PubMed ID: 29532558
    [Abstract] [Full Text] [Related]

  • 17. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C, Zou Q, Liu H, Qiu B, Li Q, Lin Y, Liang Y.
    Curr Treat Options Oncol; 2020 Apr 18; 21(4):33. PubMed ID: 32306194
    [Abstract] [Full Text] [Related]

  • 18. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
    Yin L, Lu Y.
    Zhongguo Fei Ai Za Zhi; 2018 Jul 20; 21(7):553-559. PubMed ID: 30037377
    [Abstract] [Full Text] [Related]

  • 19. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
    Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, Yano S, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K.
    Int J Clin Oncol; 2024 Aug 20; 29(8):1142-1151. PubMed ID: 38758397
    [Abstract] [Full Text] [Related]

  • 20. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
    Liu SY, Gou LY, Li AN, Lou NN, Gao HF, Su J, Yang JJ, Zhang XC, Shao Y, Dong ZY, Zhou Q, Zhong WZ, Wu YL.
    J Thorac Oncol; 2016 Sep 20; 11(9):1503-10. PubMed ID: 27257131
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.